First development candidate selected, NRG5051, with potential to treat Parkinson’s and Amyotrophic Lateral Sclerosis (ALS) (also known as Motor Neuron Disease, MND) and other neurodegenerative diseases NRG5051 prevents mitochondrial dysfunction via inhibition of the mitochondrial permeability transition pore (mPTP) through a novel protein target Inhibition of the mPTP in the brain prevents neuronal cell death […]
https://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.png00Webadmhttps://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.pngWebadm2024-10-31 08:00:292026-09-10 13:58:41NRG Therapeutics Selects First Development Candidate, NRG5051, and Secures Grant from The Michael J. Fox Foundation for Development of mPTP Inhibitors to Treat Neurodegenerative Diseases
Stevenage, UK, 5 August 2024 – NRG Therapeutics, Ltd., an innovative neuroscience company targeting mitochondrial dysfunction, is pleased to announce that it has been awarded a non-dilutive grant from Target ALS Foundation. It is one of five recipients of the 2024 In Vivo Target Validation grants in collaboration with Biospective. The funding will be used […]
https://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.png00Webadmhttps://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.pngWebadm2024-09-05 08:00:332026-07-31 12:11:57NRG Therapeutics Awarded Grant Funding from Target ALS to Support the Development of mPTP Inhibitors as Novel Treatments for ALS/MND
Stevenage, UK, 26 April 2023 – NRG Therapeutics, Ltd., an innovative neuroscience company targeting mitochondrial dysfunction, is pleased to announce that it has appointed Jonathan Savidge Ph.D to its Board of Directors as independent Non-Executive Chair. Jonathan’s appointment reflects the maturation of the company, having closed its series A financing of £16m in late 2022. […]
https://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.png00Webadmhttps://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.pngWebadm2023-04-26 08:00:342026-09-10 14:01:10NRG Therapeutics Appoints Dr Jonathan Savidge as Independent Chair
Vad Lazari Ph.D., appointed to newly created position of VP of Biology, based in Stevenage, UK Joins from Charles River and brings two decades of drug discovery experience including at Pfizer and BioFocus DPI Will be responsible for leading the biology to support NRG’s pipeline of potential first-in-class brain-penetrant small molecule inhibitors of the mitochondrial […]
https://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.png00Webadmhttps://www.nrgtherapeutics.com/wp-content/uploads/2026/07/NRG_Logo.pngWebadm2023-04-19 08:00:502026-07-31 12:21:39NRG Therapeutics Appoints Vad Lazari Ph.D. as Vice President of Biology to Advance its Mitochondrial Therapeutics for Neurodegenerative Disorders
NRG Therapeutics Selects First Development Candidate, NRG5051, and Secures Grant from The Michael J. Fox Foundation for Development of mPTP Inhibitors to Treat Neurodegenerative Diseases
First development candidate selected, NRG5051, with potential to treat Parkinson’s and Amyotrophic Lateral Sclerosis (ALS) (also known as Motor Neuron Disease, MND) and other neurodegenerative diseases NRG5051 prevents mitochondrial dysfunction via inhibition of the mitochondrial permeability transition pore (mPTP) through a novel protein target Inhibition of the mPTP in the brain prevents neuronal cell death […]
NRG Therapeutics Awarded Grant Funding from Target ALS to Support the Development of mPTP Inhibitors as Novel Treatments for ALS/MND
Stevenage, UK, 5 August 2024 – NRG Therapeutics, Ltd., an innovative neuroscience company targeting mitochondrial dysfunction, is pleased to announce that it has been awarded a non-dilutive grant from Target ALS Foundation. It is one of five recipients of the 2024 In Vivo Target Validation grants in collaboration with Biospective. The funding will be used […]
NRG Therapeutics Appoints Dr Jonathan Savidge as Independent Chair
Stevenage, UK, 26 April 2023 – NRG Therapeutics, Ltd., an innovative neuroscience company targeting mitochondrial dysfunction, is pleased to announce that it has appointed Jonathan Savidge Ph.D to its Board of Directors as independent Non-Executive Chair. Jonathan’s appointment reflects the maturation of the company, having closed its series A financing of £16m in late 2022. […]
NRG Therapeutics Appoints Vad Lazari Ph.D. as Vice President of Biology to Advance its Mitochondrial Therapeutics for Neurodegenerative Disorders
Vad Lazari Ph.D., appointed to newly created position of VP of Biology, based in Stevenage, UK Joins from Charles River and brings two decades of drug discovery experience including at Pfizer and BioFocus DPI Will be responsible for leading the biology to support NRG’s pipeline of potential first-in-class brain-penetrant small molecule inhibitors of the mitochondrial […]